Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Carcinoma, Transitional Cell 9Carcinoma, Renal Cell 8Colorectal Neoplasms 7Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Neoplasm Metastasis 6Squamous Cell Carcinoma of Head and Neck 4Recurrence 3Glioblastoma 3Carcinoma, Neuroendocrine 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Sarcoma 2Neuroendocrine Tumors 2Kidney Neoplasms 2Kidney Diseases 2Head and Neck Neoplasms 2Glioma 2Fallopian Tube Neoplasms 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Testicular Diseases 1

Interventions

niraparib 1avelumab 1Ocoxin 1Chorionic Gonadotropin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gonadal Disorders × avelumab × Clear all
NCT03403777 2019-03-05

Avelumab in Refractory Testicular Germ Cell Cancer.

National Cancer Institute, Slovakia

Phase 2 Completed
8 enrolled
Genitourinary

Gonadal Disorders, Neoplasms, Neoplasms, Germ Cell and Embryonal, Testicular Diseases, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡